Xiang Chen, Tong-Tao Yang, and Yong Zhou contributed equally to this work.
Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma
Article first published online: 4 SEP 2012
© 2012 Wiley Periodicals, Inc.
Volume 53, Issue 2, pages 138–144, February 2014
How to Cite
Chen, X., Yang, T.-T., Zhou, Y., Wang, W., Qiu, X.-C., Gao, J., Li, C.-X., Long, H., Ma, B.-A., Ma, Q., Zhang, X.-z., Yang, L.-J. and Fan, Q.-Y. (2014), Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma. Mol. Carcinog., 53: 138–144. doi: 10.1002/mc.21957
- Issue published online: 22 JAN 2014
- Article first published online: 4 SEP 2012
- Manuscript Accepted: 9 AUG 2012
- Manuscript Revised: 2 AUG 2012
- Manuscript Received: 3 MAY 2012
Osteosarcoma (OSA) is the most common primary malignancy of bone. Molecular mechanism underlying OSA remains to be fully elucidated. It is critical to identify reliable diagnostic and prognostic markers for OSA at the molecular levels. This study is designed to investigate possible molecular mechanisms behind OSA development and to identify novel prognostic markers related to OSA survival. We conduct a comprehensive proteomic profiling analysis of human OSA cell lines with differential metastatic potential. Through comprehensive combinatorial analyses of the proteomic data and the previously obtained cDNA microarray results, we identify 37 candidate proteins which are differentially expressed in OSA sublines. Among them, ALDOA and SULT1A3 are selected for further investigation. The expressions of protein are confirmed by Western blotting analysis. We further analyze the expression levels of ALDOA and SULT1A3 from 40 clinical cases of OSA. The results demonstrate that the expression of ALDOA and/or SULT1A3 is significantly higher in patients with worse survival time than patients with better survival time. Five-year survival analysis shows there is a statistically significant difference between two patient populations. The data strongly suggest that ALDOA and/or SULT1A3 expression level in biopsy samples may predict the clinical outcomes of OSA patients. Furthermore, the biological functions of ALDOA and SULT1A3 may be implicated in OSA development and/or progression. © 2012 Wiley Periodicals, Inc.